Mode
Text Size
Log in / Sign up
N/A Completed N=1,184 Randomized Single-blind Treatment

Message-Based Psychotherapy and Digital Treatment Sequences for Depression

Study Adherence · Depressive Symptoms
Source: ClinicalTrials.gov NCT04513080 ↗
Enrolled (actual)
1,184
Serious AEs
0.1%
Results posted
Oct 2025
Primary outcomePrimary: Change in Neuro-QOL - Ability to Participate in Social Roles and Activities — 39.55; 39.57; 41.65; 42.07 T-score

Summary

This partnership between Talkspace and the University of Washington (UW) ALACRITY Center will determine how effective unlimited text-based psychotherapy for depression is when compared to once-a-week psychotherapy. This study will also determine what the best treatment options are for people who are not responding well to either unlimited texting or weekly psychotherapy. The results of this study will be a new product version of message-based care that can tailor psychotherapy intensity based on the needs of future consumers with depression.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Neuro-QOL - Ability to Participate in Social Roles and Activities
39.55; 39.57; 41.65; 42.07; 43.39; 43.11
PRIMARY
Change in Patient Health Questionnaire (PHQ-9)
15.06; 15.30; 14.48; 15.14; 14.85; 15.09
SECONDARY
Change in Generalized Anxiety Disorder (GAD-7)
12.22; 12.06; 14.76; 14.67; 13.27; 13.33

Eligibility Criteria

Inclusion and exclusion criteria are the same for Phase 1 and Phase 2.

Inclusion Criteria

  • 18 years old or older
  • English or Spanish speaking
  • Live in the United States
  • Score of 10 or greater on the Patient Health Questionnaire-9 (PHQ-9) screening
  • Receive a diagnosis of depression from a Talkspace intake clinician

Exclusion Criteria

  • Under the age of 18
  • Non-English or Spanish speaking
  • Do not meet criteria for a depressive disorder
  • Participants with active suicidal ideation or with a primary diagnosis of psychosis will also be excluded and referred to intensive care.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04513080). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search